Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04692493 · ClinicalTrials.gov registry record · Phase 3
Ra-pro Pragmatic Trial
A Phase 3 study of Rheumatoid Arthritis, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 924
- Enrollment target
- 20
- Study locations
NCT04692493 is a Phase 3 study of Rheumatoid Arthritis that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 924 participants, below the 4,686-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT04692493, a Phase 3 study of Rheumatoid Arthritis, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 924 participants
- Enrollment target
- 20
- Study locations
Study Summary
The 2021 ACR RA treatment guideline, based on widely acknowledged low to moderate quality evidence, recommends switching to a non-tumor necrosis factor (TNFi) biologic (choose among existing medications, currently, rituximab, abatacept, tocilizumab, or sarilumab) or a targeted synthetic DMARD arm (tsDMARD; choose among existing medications, currently, tofacitinib, baricitinib, upadacitinib) in patients with active RA despite the use of a TNFi-biologic. In practice, most patients receive another TNFi-biologic, i.e., a second TNFi-biologic first. This is not based on solid evidence, but on arbitrary algorithms often proposed by health insurance plans, and/or physician experience and habit (TNFis launched 22 yrs ago vs. the first tsDMARD 8 years ago vs. first non-TNF-biologic launched 17 years ago). This study will fill a critical knowledge gap by generating CER data for important PROs between these treatment options, switching to a non-TNFi biologic or a tsDMARD in patients with active RA despite the use of a TNFi-biologic.
Conditions Studied
Interventions
- DRUG targeted synthetic DMARD class
- DRUG non-TNFi-biologic class
Study Locations (20)
Florida
- George Munoz MD, PC - Aventura
- American Arthritis and Rheumatology Associates LLC - Clearwater
- CZ Rheumatology - Coral Springs
- American Arthritis and Rheumatology Associates LLC - Fort Lauderdale
- Mayo Clinic Jacksonville - Jacksonville
- Palm Beach Rheumatology and Wellness - Jupiter
- Arthritis & Rheumatology Center of South Florida - Margate
- Life Medical Research Group - Miami Gardens
- Southwest Florida Rheumatology - Riverview
California
- Pacific Arthritis Care Center - Los Angeles
- University of California, Los Angeles - Los Angeles
- Arthritis Medical Center - Nipomo
- Turlock Arthritis & Osteoporosis Center, - Turlock
- Center for Rheumatology Research - Woodland Hills
Alabama
- East Alabama Arthritis Center PC - Auburn
- Bendcare, LLC - Birmingham
- University of Alabama at Birmingham - Birmingham
Arizona
- SunValley Arthritis Center, Ltd - Peoria
- University of Arizona - Tucson
Georgia
- Southeast Georgia Physician Associates-Rheumatology - Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 924 participants |
| Start Date | 2021-09-22 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04692493
The ClinicalTrials.gov registry entry for NCT04692493 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 924 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,686-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (80% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which targeted synthetic DMARD class is the first listed.
NCT04692493 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT04692493 about?
NCT04692493 is a clinical study titled "Ra-pro Pragmatic Trial". The 2021 ACR RA treatment guideline, based on widely acknowledged low to moderate quality evidence, recommends switching to a non-tumor necrosis factor (TNFi) biologic (choose among existing medications, currently, rituximab, abatacept, tocilizumab, or sarilumab) or a targeted synthetic DMARD arm (t...
What is the current status of trial NCT04692493?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 924 participants. The study started on 2021-09-22. Estimated completion is 2028-12-31.
What conditions does trial NCT04692493 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT04692493?
The interventions under investigation include: targeted synthetic DMARD class (DRUG), non-TNFi-biologic class (DRUG).
Who is sponsoring clinical trial NCT04692493?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04692493 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
RECRUITING · Phase 3
-
Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
ACTIVE NOT RECRUITING · Phase 3
-
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
ACTIVE NOT RECRUITING · Phase 3
-
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.